MATCHPOINT - Medulloblastoma Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade
This study is testing a new combination treatment for children and young adults whose fast-growing brain tumor, called medulloblastoma, has returned or worsened after previous treatment. Researchers want to see if using personalized immune-boosting therapies together can help the body's own defense system fight the cancer.
Patients aged 4 to 30 years old with a returning or worsening Group 3 or Group 4 medulloblastoma who have finished radiation and can undergo a surgery or biopsy may join. Participants must also meet general health and organ function requirements.
Participants will receive specialized treatments made from their own tumor cells, including personalized vaccines and immune therapy drugs, along with their own stored stem cells to help the body recover. They will also receive a standard tetanus booster shot to help stimulate their immune system.
This study is currently recruiting patients and takes place in Washington, D.C., and Gainesville, Florida, in the United States.
- 1Testing a personalized immune system treatment for returning brain tumors.
- 2Open to children and young adults aged 4 to 30 years old.
- 3Currently recruiting patients at locations in Washington D.C. and Florida.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.